Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens

Berthony Deslouches, Jonathan D. Steckbeck, Jodi K. Craigo, Yohei Doi, Jane L. Burns, Ronald C. Montelaro

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.

Original languageEnglish
Pages (from-to)1329-1333
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume59
Issue number2
DOIs
Publication statusPublished - 01-02-2015
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens'. Together they form a unique fingerprint.

  • Cite this